Please make a donation to the Aplastic Anemia and MDS International Foundation this holiday season.
Steroid-refractory GvHD (SR-GvHD) following allogeneic transplant is a major clinical challenge and is associated with substantial mortality [1].
In this issue of Blood, Takashima et al show that reduced STAT1 abundance in SRSF2-mutant myelodysplastic syndrome (MDS) cells confers protection against interferon (IFN)-driven cell suppression relative to normal wild-type (WT) cells.1 Importantly, the authors demonstrate that treatment with the proteasome inhibitor bortezomib in vitro increases STAT1 abundance and sensitizes SRSF2-mutant cells to IFN. These findings provide potential rationale for using bortezomib therapy in SRSF2-mutated MDS, which is characterized by poor outcomes.
Abstract
Abstract
Purpose
Hello Friends, Family, and our AAMDSIF Family!
We are excited to announce our upcoming Halloween Benefit Bash, where we aim to celebrate life and raise funds for the AA&MDS International Foundation—an organization that has provided incredible support to my family and many others throughout our journeys.
Tickets for this event are $50 each, and while we welcome any additional donations, your presence at the event would mean the world to us. If you're unable to attend but would like to contribute, we would greatly appreciate your support.
Market Research Study If you are interested in learning more about your possible participation in this study, please complete the form. Your information will be forwarded directly to the study sponsor.
Non-therapeutic Study If you are interested in learning more about your possible participation in this study, please complete the form. Your information will be forwarded directly to the study coordinator.